Literature DB >> 7304653

The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer.

M W Ashcraft, A J Van Herle.   

Abstract

This study is an attempt to unify the evaluation of patients with well-differentiated thyroid cancer after ablative therapy. As such serum thyroglobulin determinations on and off thyroid hormone (T4) therapy and iodine 131 total body scans were examined in 53 patient studies. No metastases were found in patients whose thyroglobulin value was undetectable (less than 1 ng/ml). Values during T4 therapy that were detectable, even as low as 4.2 ng/ml, were occasionally associated with metastases. After T4 withdrawal, thyroglobulin value and scan were obtained. Neither metastasis nor clinically detectable cancer was found in patients whose thyroglobulin value was less than 10 ng/ml while off T4. Conversely, a value greater than 10 ng/ml was often associated with documented metastases even when the scan was negative. In summary, a thyroglobulin value less than 1 ng/ml during T4 therapy or less than 10 ng/ml off T4 therapy suggests successful therapy and a routine scan could be avoided unless clinically indicated. However, a value greater than 10 ng/ml suggests the presence of metastasis despite a negative scan. Thyroglobulin determination substantially improves the management of these patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7304653     DOI: 10.1016/0002-9343(81)90368-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  22 in total

1.  Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.

Authors:  A S Alzahrani; G Mohamed; A Al Shammary; S Aldasouqi; S Abdal Salam; M Shoukri
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

2.  Increased heterogeneity of serum thyroglobulin in thyroid cancer patients as determined by monoclonal antibodies.

Authors:  B Heilig; M Hüfner; B Dörken; H Schmidt-Gayk
Journal:  Klin Wochenschr       Date:  1986-09-01

3.  Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer.

Authors:  D Rubello; M E Girelli; D Casara; M Piccolo; A Perin; B Busnardo
Journal:  J Endocrinol Invest       Date:  1990-10       Impact factor: 4.256

4.  Histochemical demonstration of thyroxine, triiodothyronine, and thyroglobulin in the primary lesion of thyroid carcinoma, and its predictability for radioiodine uptake by metastatic lesions.

Authors:  T Kodama; Y Fujimoto; T Obara; Y Ito; K Kusakabe; A Hirayama
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

5.  Critical evaluation of serum thyroglobulin (Tg) levels during thyroid hormone suppression therapy versus Tg levels after hormone withdrawal and total body scan: results in 291 patients with thyroid cancer.

Authors:  M E Girelli; B Busnardo; R Amerio; D Casara; C Betterle; M Piccolo
Journal:  Eur J Nucl Med       Date:  1986

Review 6.  Post-surgical follow-up of differentiated thyroid cancer.

Authors:  F Pacini; R Elisei; L Fugazzola; F Cetani; C Romei; F Mancusi; A Pinchera
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

7.  False positive 131I total body scan due to an ectasia of the common carotidis.

Authors:  D Giuffrida; M R Garofalo; G Cacciaguerra; V Freni; A Ippolito; C Regalbuto; M G Santonocito; A Belfiore
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

8.  [Long-term observation of 15 patients with differentiated thyroid cancer and elevated plasma thyroglobulin levels of unclear origin].

Authors:  H P Stumpf; M Hüfner; H J Hermann; B Kimmig
Journal:  Klin Wochenschr       Date:  1984-05-02

9.  Immunoreactive thyroglobulin in sera and saliva of patients with various thyroid disorders: role of autoantibodies.

Authors:  A J Van Herle; P D Rosenblit; T L Van Herle; P Van Herle; M Greipel; K Kellett
Journal:  J Endocrinol Invest       Date:  1989-03       Impact factor: 4.256

10.  Practice trends in patients with persistent detectable thyroglobulin and negative diagnostic radioiodine whole body scans: a survey of American Thyroid Association members.

Authors:  Robert C Smallridge; Nancy Diehl; Victor Bernet
Journal:  Thyroid       Date:  2014-09-05       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.